<DOC>
	<DOC>NCT02089360</DOC>
	<brief_summary>Blood sample is prospectively taken from consecutive patients underwent coronary angiogram in our center, after getting informed consent from the patients. Serum level of advanced glycation end products (AGEs) was measured and the clinical features of patients (including angiographic results) were entered into our database. Clinical follow-up was performed for all patients, and the relationship between AGEs and paitents' outcome were analyzed. Further intervention will be adjusted according to the results,including clinical and basic research in lab.</brief_summary>
	<brief_title>Adavanced Glycated Endproducts and Development of CAD</brief_title>
	<detailed_description>Serum levels of HMGB1, HMGB2, ADAM10, etc. will be measured in lab and animal studies will be designed to intervene the adverse interaction between abnormal serum concentration of AGEs, etc. and worse clinical results.</detailed_description>
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Atherosclerosis</mesh_term>
	<criteria>patients underwent coronary angiogram for suspected coronary artery disease and potential percutaneous coronary intervention patients underwent coronary angiogram for other reasons, including presurgery examination patients with severe comorbidity, and life expectancy less than oneyear</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Advanced glycation end product</keyword>
	<keyword>coronary</keyword>
	<keyword>atherosclerosis</keyword>
	<keyword>inflammation</keyword>
	<keyword>outcome</keyword>
</DOC>